NCT00143247View on ClinicalTrials.gov

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

PHASE2TerminatedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Diabetes Mellitus
Interventions
DRUG

Exubera® (inhaled insulin)

Treatment of type 1 and type 2 diabetes with short-acting insulin

Trial Locations (12)

27157

Pfizer Investigational Site, Winston-Salem

27710

Pfizer Investigational Site, Durham

33136

Pfizer Investigational Site, Miami

60610

Pfizer Investigational Site, Chicago

75230

Pfizer Investigational Site, Dallas

75243

Pfizer Investigational Site, Dallas

78229

Pfizer Investigational Site, San Antonio

78752

Pfizer Investigational Site, Austin

78758

Pfizer Investigational Site, Austin

92123

Pfizer Investigational Site, San Diego

06504

Pfizer Investigational Site, New Haven

87131-5666

Pfizer Investigational Site, Albuquerque

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00143247 - Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter